Get started
Author

Khalid D. Benbatoul

Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance.
2000 · M J Newman, J C Rodarte, et al. · PubMed · 191
APTO-253 Stabilizes G-quadruplex DNA, Inhibits MYC Expression, and Induces DNA Damage in Acute Myeloid Leukemia Cells
2018 · Andrea Local, Hongying Zhang, et al. · Molecular Cancer Therapeutics · 83
PDF
Antiinflammatory glucocorticoid receptor ligand with reduced side effects exhibits an altered protein–protein interaction profile
2007 · Jeffrey N. Miner, Bob Ardecky, et al. · Proceedings of the National Academy of Sciences · 68
2,4,5-Trisubstituted imidazoles
2000 · Chengzhi Zhang, Sepehr Sarshar, et al. · Bioorganic & Medicinal Chemistry Letters · 62
Novel regions of allelic deletion on chromosome 18p in tumors of the lung, brain and breast
1998 · Yen Tran, Khalid Benbatoul, et al. · Oncogene · 54
LGD-5552, an Antiinflammatory Glucocorticoid Receptor Ligand with Reduced Side Effects, in Vivo
2008 · Francisco J. López, Robert J. Ardecky, et al. · Endocrinology · 53
PDF
2,4,5-Trisubstituted imidazoles
2000 · Sepehr Sarshar, Chengzhi Zhang, et al. · Bioorganic & Medicinal Chemistry Letters · 44
Quantitation of the change in GADD153 messenger RNA level as a molecular marker of tumor response in head and neck cancer.
1999 · G Los, K Benbatoul, et al. · PubMed · 23
2,4,5-三置換イミダゾール P-糖蛋白質媒介多剤耐性の新規無毒モジュレータ 2
2000 · C Zhang, Sepehr Sarshar, et al. · Bioorganic & Medicinal Chemistry Letters · 19
Identification of a potent and rapidly reversible inhibitor of the 20S-proteasome
2004 · Ashok V. Purandare, Honghe Wan, et al. · Bioorganic & Medicinal Chemistry Letters · 17
Increase in tumor GADD153 mRNA level following treatment correlates with response to paclitaxel
2000 · Maida M. de las Alas, Randolph D. Christen, et al. · Cancer Chemotherapy and Pharmacology · 11
A Phase 1 a/b Dose Escalation Study of the Mutation Agnostic BTK/FLT3 Inhibitor CG-806 in Patients with Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas
2020 · Rafael Bejar, Hongying Zhang, et al. · Blood · 8
A Phase 1a/b Dose Escalation Study of the Mutation Agnostic FLT3/BTK Inhibitor Luxeptinib (CG-806) in Patients with Relapsed or Refractory Acute Myeloid Leukemia
2021 · Aaron D Goldberg, Maro Ohanian, et al. · Blood · 5
A Phase 1a/b Dose Escalation Study of the Mutation Agnostic BTK/FLT3 Inhibitor Luxeptinib (CG-806) in Patients with Relapsed or Refractory B-Cell Malignancies
2021 · Felipe Samaniego, John M. Burke, et al. · Blood · 5
Inhibition of c-Myc By Apto-253 As an Innovative Therapeutic Approach to Induce Cell Cycle Arrest and Apoptosis in Acute Myeloid Leukemia
2016 · Hongying Zhang, Andrea Local, et al. · Blood · 5
A Phase 1a/b Dose Escalation Study of the MYC Repressor Apto-253 in Patients with Relapsed or Refractory AML or High-Risk MDS
2020 · Rafael Bejar, Hongying Zhang, et al. · Blood · 4
ChemInform Abstract: 2,4,5‐Trisubstituted Imidazoles: Novel Nontoxic Modulators of P‐Glycoprotein Mediated Multidrug Resistance. Part 2.
2001 · Chengzhi Zhang, Sepehr Sarshar, et al. · ChemInform · 4
Abstract 794: CG'806, a first-in-class pan-FLT3/pan-BTK inhibitor, targets multiple pathways to kill diverse subtypes of acute myeloid leukemia and B-cell malignancy in vitro
2018 · Hongying Zhang, Andrea Local, et al. · Cancer Research · 3
Abstract 4225: CG-806, a first-in-class FLT3/BTK inhibitor, and venetoclax synergize to inhibit cell proliferation and to induce apoptosis in aggressive B-cell lymphomas
2020 · Nasrin Rastgoo, Matthew Thayer, et al. · Cancer Research · 2
CG'806, a First-in-Class Pan-FLT3/Pan-BTK Inhibitor, Exhibits Broader and Greater Potency Than Ibrutinib Against Primary and Cultured Malignant B Cells
2018 · Hongying Zhang, Andrea Local, et al. · Blood · 2
Abstract 44: CG′806, a first-in-class FLT3/BTK inhibitor, exhibits potent activity against AML patient samples with mutant or wild type FLT3, as well as other hematologic malignancy subtypes
2017 · Stephen E. Kurtz, Beth Wilmot, et al. · Clinical Cancer Research · 2
APTO-253 Interaction with G-Quadruplex DNA Is Linked to Inhibition of c-Myc Expression, Induction of DNA Damage, and Generation of Synthetic Lethality in Cells with BRCA1/2 Impairment
2017 · Andrea Local, Hongying Zhang, et al. · Blood · 2
CG '806, a First-in-Class Non-Covalent Pan-FLT3/BTK Inhibitor, Exerts Superior Potency Against B-Cell Malignant Cells
2017 · Hongying Zhang, Andrea Local, et al. · Blood · 2
Abstract CT239: Early clinical findings from a phase 1a/b dose escalation trial to evaluate the safety and tolerability of CG-806 in patients with relapsed or refractory CLL/SLL or non-Hodgkin's lymphomas
2020 · Hongying Zhang, Nasrin Rastgoo, et al. · Cancer Research · 1
Pf203 Cg‐806, Preclinical in Vivo Efficacy and Safety Profile as a Pan‐flt3/pan‐btk Inhibitor
2019 · H. Zhang, K. Benbatoul, et al. · HemaSphere · 1
Works count: 38
Citation count: 672
H-index: 11
I10-index: 11
Year
Topic
Type